63 phenotypes from 2 alleles in 2 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Agpat2Gt(OST438470)Lex/Agpat2Gt(OST438470)Lex involves: 129S5/SvEvBrd * C57BL/6	abnormal brown adipose tissue morphology	J:186035
	abnormal dentin development	J:186035
	abnormal incisor morphology	J:186035
	abnormal liver morphology	J:186035
	abnormal white fat cell morphology	J:186035
	adipose tissue necrosis	J:186035
	ameloblast degeneration	J:186035
	brown adipose tissue inflammation	J:186035
	decreased body size	J:186035
	decreased brown adipose tissue amount	J:186035
	decreased white adipose tissue amount	J:186035
	decreased white fat cell number	J:186035
	decreased white fat cell size	J:186035
	distended abdomen	J:186035
	enlarged liver	J:186035
	enlarged pancreatic islets	J:186035
	femur fracture	J:186035
	granulomatous inflammation	J:186035
	hyperglycemia	J:186035
	increased circulating glucose level	J:186035
	increased circulating insulin level	J:186035
	increased pancreatic beta cell number	J:186035
	lipodystrophy	J:186035
	liver inflammation	J:186035
	microvesicular hepatic steatosis	J:186035
	pale liver	J:186035
	postnatal lethality, incomplete penetrance	J:186035
	premature death	J:186035
	reduced enamel thickness	J:186035
	rough coat	J:186035
Agpat2tm1Garg/Agpat2tm1Garg involves: 129S6/SvEvTac	abnormal abdominal fat pad morphology	J:146649
	abnormal fatty acids level	J:146649
	abnormal gas homeostasis	J:146649
	abnormal glucose homeostasis	J:146649
	abnormal lipid homeostasis	J:146649
	abnormal phospholipid level	J:146649
	abnormal small intestine morphology	J:146649
	absent subcutaneous adipose tissue	J:146649
	decreased body temperature	J:146649
	decreased body weight	J:231617
	decreased brown adipose tissue amount	J:146649
	decreased circulating free fatty acids level	J:146649
	decreased circulating leptin level	J:146649
	decreased locomotor activity	J:146649
	decreased percent body fat/body weight	J:146649
	decreased respiratory quotient	J:146649
	decreased survivor rate	J:146649
	decreased total body fat amount	J:146649
	decreased white adipose tissue amount	J:146649
	enlarged pancreatic islets	J:146649
	hepatic steatosis	J:146649
	normal homeostasis/metabolism phenotype	J:231617
	hyperglycemia	J:146649
	improved glucose tolerance	J:231617
	increased carbon dioxide production	J:146649
	increased circulating cholesterol level	J:231617
	increased circulating glucose level	J:231617
	increased circulating insulin level	J:146649, J:231617
	increased circulating triglyceride level	J:146649
	increased fluid intake	J:146649
	increased food intake	J:146649, J:231617
	increased kidney weight	J:146649
	increased liver triglyceride level	J:146649, J:231617
	increased liver weight	J:146649, J:231617
	increased oxygen consumption	J:146649
	increased pancreatic beta cell mass	J:146649
	increased spleen weight	J:146649
	insulin resistance	J:146649, J:231617
	polydipsia	J:231617
	postnatal lethality, incomplete penetrance	J:146649